No mortality benefit of early ibuprofen in preterm infants with arteriosus

DENVER — A randomized controlled trial found that early targeted treatment with ibuprofen did not reduce mortality among 72-hour-old extremely preterm infants with a large patent ductus arteriosus, researchers reported here.
There also was no benefit on moderate or severe bronchopulmonary dysplasia (BPD), although treatment was beneficial in other ways, according to data presented at the Pediatric Academic Societies Meeting.
The Baby-OSCAR trial examined infants born before 28 weeks of gestation to evaluate whether early targeted treatment of a large PDA with ibuprofen within 72 hours of

DENVER — A randomized controlled trial found that early targeted treatment with ibuprofen did not reduce mortality among 72-hour-old extremely preterm infants with a large patent ductus arteriosus, researchers reported here.
There also was no benefit on moderate or severe bronchopulmonary dysplasia (BPD), although treatment was beneficial in other ways, according to data presented at the Pediatric Academic Societies Meeting.
The Baby-OSCAR trial examined infants born before 28 weeks of gestation to evaluate whether early targeted treatment of a large PDA with ibuprofen within 72 hours of